Navigation Links
NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
Date:6/12/2012

HUBBARD, Ohio, June 13, 2012 /PRNewswire/ -- NanoLogix (OTC Markets:NNLX) announced today its R&D team in collaboration with University of Texas Health Science Center - Houston (UTHSC-Houston) researchers, are developing a multi-well, microplate reader variant of the company's BioNanoFilter (BNF) diagnostics for use in large volume laboratory environments.  Early analysis of the multi-well plates shows exceptionally fast live-threat results similar to the company's standard BNF technology.  Starting this week, the NanoLogix BNF and BioNanoPore (BNP) technology will be on exhibit at booth #841 at the 112th General Meeting of the American Society for Microbiology in San Francisco, June 16 – June 19.

(Photo:  http://photos.prnewswire.com/prnh/20120613/CL23734)

Research using NanoLogix technology from a recently completed clinical study will also be presented at the ASM General Meeting on June 17th.  Dr. Jonathan Faro of UTHSC-Houston will present the research, which focused on detection, identification, and determination of antibiotic sensitivity of Group B Streptococcus (GBS) during pregnancy.  Data showed NanoLogix diagnostics consistently provided results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours.  The data and the associated clinical study narrative is currently being formatted for submission for peer-review publication, as well as to the US FDA for acceptance as a non-invasive diagnostic technology. 

"These are exciting times for NanoLogix," said CEO Bret Barnhizer.  "Our technology has the potential to dramatically affect the course of human health and events over the past eight months have greatly enhanced our position for the future."   

Rapid Live-Threat Tuberculosis Results

Recent R&D operations have also converged to dramatically enrich NanoLogix' bacteria and protozoa detection technology portfolio.

The detection for Tuberculosis (TB) utilizing NanoLogix' BNF and BioNanoPore (BNP) technologies has recently been completed by a major independent, third-party research laboratory.  Live-threat TB was detected with NanoLogix BNP technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture.  TB was also detected and identified with the company's BNF technology in less than two hours.  Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.

"We are thrilled to be dramatically cutting bacterial detection times from days to hours for many pathogens," said Barnhizer.  "Specifically, we have reduced wait times for TB from weeks to days, while protozoa detection times for Cryptosporidium, which is responsible for over 50 percent of waterborne illnesses, have been cut from weeks to hours.  At the same time, we have been able to accomplish these results with improved quality of detection."

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit  www.nanologix.com.

Media Contact:
Lisa Ann Pinkerton
Technica Communications for NanoLogix
408-806-9626
lisaann@technicacommunications.com

Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

 


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. NanoLogix Provides Testing and Operations Update
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
Breaking Biology News(10 mins):